Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | SNCA | P37840 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.61 |
| ▸ | DHODH | Q02127 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | CDC25A | P30304 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974934 | 1.00 | MAPT (0.74) | MAPTPGRHTR1AADORA3PTGS1 | |
| SCHEMBL6496757 | 0.91 | PTGS1 (0.82) | MAPTPGRHTR1AADORA3PTGS1 | |
| Lapachol SCHEMBL157255 | 0.87 | DHODH (0.79) | MAPTPGRHTR1AADORA3PTGS1 | |
| Lapachol SCHEMBL31492698 | 0.87 | DHODH (0.79) | MAPTPGRHTR1AADORA3PTGS1 | |
| Menaquinone-2 SCHEMBL571905 | 0.86 | PTGS1 (0.97) | MAPTPGRHTR1AADORA3PTGS1 | |
| Menaquinone-2 SCHEMBL30606255 | 0.86 | PTGS1 (0.97) | MAPTPGRHTR1AADORA3PTGS1 | |
| Menaquinone-2 SCHEMBL29355593 | 0.86 | PTGS1 (0.97) | MAPTPGRHTR1AADORA3PTGS1 | |
| Menaquinone-2 SCHEMBL416517 | 0.86 | PTGS1 (0.97) | MAPTPGRHTR1AADORA3PTGS1 | |
| Lapachol SCHEMBL18769814 | 0.85 | DHODH (0.77) | MAPTPGRHTR1AADORA3PTGS1 | |
| Lapachol SCHEMBL3274147 | 0.85 | DHODH (0.77) | MAPTPGRHTR1AADORA3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532390-B1 | Pharmaceutical composition for liver diseases. | MD BIOALPHA CO LTD (KR) | 2016-08-17 | — | — | EP | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | KT & G CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| EP-1848432-B1 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO LTD (KR) | 2013-07-17 | — | — | EP | disclosed |
| US-8466141-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2013-06-18 | — | — | US | disclosed |
| EP-2532390-A2 | Pharmaceutical composition for obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | Md Bioalpha Co., Ltd. (KR) | 2012-12-12 | — | — | EP | disclosed |
| EP-2532388-A2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | Md Bioalpha Co., Ltd. (KR) | 2012-12-12 | — | — | EP | disclosed |
| EP-2532389-A2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | Md Bioalpha Co., Ltd. (KR) | 2012-12-12 | — | — | EP | disclosed |
| US-20120114714-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION | KWAK TAEHWAN (KR) | 2012-05-10 | — | — | US | disclosed |
| US-20110020448-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | MAZENCE, INC. (KR) | 2011-01-27 | — | — | US | disclosed |
| US-20100239674-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | KT & G CO., LTD. (KR) | 2010-09-23 | — | — | US | disclosed |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| EP-2099449-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | Mazence Inc. (KR) | 2009-09-16 | — | — | EP | disclosed |
| EP-2099448-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | Mazence Inc. (KR) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009082124-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | MAZENCE INC. (KR) | 2009-07-02 | — | — | WO | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066297-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066299-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| EP-1848432-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | Md Bioalpha Co., Ltd. (KR) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006088315-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114714-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION | PDE3A, PDE3B, PDE2A | MAPT 1140/4885PGR 1155/4885HTR1A 505/4885 |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | SLC25A20, SLC25A1, PC | MAPT 292/4885PGR 2870/4885HTR1A 1909/4885 |
| US-20110020448-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | PDE3A, SLC5A1, GUCY1B1 | MAPT 453/4885PGR 3041/4885HTR1A 2853/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | MAPT 308/4885PGR 3363/4885HTR1A 1447/4885 |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | NLN, SLC25A20, ACAD9 | MAPT 586/4885PGR 2914/4885HTR1A 1340/4885 |
| US-20100239674-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | PDE3A, PDE3B, PDE2A | MAPT 888/4885PGR 908/4885HTR1A 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.